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a b s t r a c t
Primordial germ cells (PGCs) are the founder cells of the germline. Via gametogenesis and fertilisation
this lineage generates a new embryo in the next generation. PGCs are also the cell of origin of
multilineage teratocarcinomas. In vitro, mouse PGCs can give rise to embryonic germ (EG) cells –
pluripotent stem cells that can contribute to primary chimaeras when introduced into pre-implantation
embryos. Thus, PGCs can give rise to pluripotent cells in the course of the developmental cycle, during
teratocarcinogenesis and by in vitro culture. However, there is no evidence that PGCs can differentiate
directly into somatic cell types. Furthermore, it is generally assumed that PGCs do not contribute to
chimaeras following injection into the early mouse embryo. However, these data have never been
formally published. Here, we present the primary data from the original PGC-injection experiments
performed 40 years ago, alongside results from more recent studies in three separate laboratories. These
results have informed and inﬂuenced current models of the relationship between pluripotency and the
germline cycle. Current technologies allow further experiments to conﬁrm and expand upon these
ﬁndings and allow deﬁnitive conclusions as to the developmental potency of PGCs.
& 2013 The Authors. Published by Elsevier Inc.
Introduction
In mammals, cells of both the early embryo and the germline
may be considered to maintain full developmental potency and
can be incorporated into an exclusive cycle that is exited upon
somatic differentiation (Leitch and Smith, 2013; Leitch et al.,
2013c; Monk, 1990, 1981; Pesce et al., 1998). Although competence
for pluripotency is maintained throughout, cells at different stages
of the germline cycle have different functional properties. In the
mouse embryo, cells of the inner cell mass, speciﬁcally the pre-
implantation epiblast, can contribute to chimaeras including the
germline, following blastocyst injection (Gardner, 1985, 1968;
Gardner and Rossant, 1979). Furthermore, embryonic stem (ES)
cell lines derived from the pre-implantation epiblast maintain this
capacity following in vitro culture (Bradley et al., 1984). Such
proven capacity to reintegrate into the embryo and contribute
functionally into development of all somatic lineages and the
germline are attributes associated with the term naïve pluripo-
tency (Nichols and Smith, 2009). Strikingly, naïve pluripotent stem
cell lines, called embryonic germ (EG) cells, can also be derived
from primordial germ cells (PGCs) at later stages of embryogenesis
(Matsui et al., 1992; Resnick et al., 1992). Indeed, recent studies
have demonstrated that early PGCs can give rise to pluripotent
stem cell lines with an efﬁciency comparable to that of the pre-
implantation epiblast (Leitch et al., 2013b; Nichols et al., 2009;
Rugg-Gunn et al., 2012). Once established, EG cells may be
indistinguishable from ES cells functionally and at the molecular
level (Leitch et al., 2010, 2013a; Sharova et al., 2007). Thus, EG cells
can only be deﬁnitively distinguished from ES cells by their origin.
Although PGCs can give rise to EG cells in vitro and are the cell of
origin of multilineage testicular teratocarcinomas (Stevens, 1967),
during normal development they appear to give rise exclusively to
the gametes. The presumption in the ﬁeld has been that PGCs do
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not contribute to primary chimaeras, consistent with not being in
an equivalent pluripotent state to the cells of the pre-implantation
epiblast. However, the primary blastocyst injection data, although
informally communicated to the scientiﬁc community (Leitch and
Smith, 2013; Matsui, 1998; Rossant, 1993), has never been pub-
lished. Here we present the original experimental data obtained by
two of us (V.E.P. and R.L.G.) alongside unpublished ﬁndings from
subsequent studies by Colin Stewart (C.L.S) and Matsui (D.O. and Y.
M.) and McLaren (G.D.) laboratories. We discuss the impact of
these experiments on current perception of the mammalian
germline and pluripotency, and highlight unanswered questions.
Results – PGC blastocyst injections across four decades
The technique for producing mouse chimaeras by blastocyst
injection rather than via morula aggregation was devised more
than four decades ago (Gardner, 1998, 1968). This advance enabled
the Gardner laboratory to test rigorously the ability of different cell
populations to reintegrate into mouse embryogenesis. These
studies demonstrated that cells of the pre-implantation epiblast
but not the hypoblast (primitive endoderm) could contribute
extensively to chimaeras and produce functional gametes
(Gardner, 1985; Gardner and Rossant, 1979). They also found that
the capacity for functional incorporation into the blastocyst is lost
after implantation (Rossant et al., 1978). Remarkably, tumour-
derived teratocarcinoma cells and embryonal carcinoma (EC) cell
lines could also contribute to blastocyst injection chimaeras, albeit
they frequently induced embryonic lethality or produced tumours
in the offspring, and did not give rise to germline transmission
(Papaioannou et al., 1978, 1975). Thus, pluripotency appears to be
compromised during the cellular transformation associated with
teratocarcinogenesis. As PGCs are the cell of origin of testicular
teratocarcinoma (Stevens, 1967) there was an obvious rationale to
test PGCs in the blastocyst injection assay. However, in 1972,
without modern molecular labelling techniques, this was not a
facile undertaking (Fig. 1A). To isolate PGCs, the genital ridges of
male embryos at either E10.5 or E11.5 were dissected, enzymati-
cally digested and PGCs manually picked based on morphology.
The purity of the separated PGCs was assessed by alkaline
phosphatase staining of a small aliquot, and was found to be
between 40% and 100% (median 72%) across ﬁve different experi-
ments. Two or more PGCs were then injected into the blastocoel
cavity and the injected blastocysts transferred to pseudopregnant
hosts. The pregnant females were left to term resulting in 44 live
births (20 females and 24 males) in total, 15 of which were derived
from blastocysts injected with E10.5 PGCs and the remainder from
injection of E11.5 PGCs (Fig. 1B). The donor PGCs were isolated
from extreme non-agouti (ae/ae) embryos of the AG/Cam strain or
F1 embryos from AG/Cam x CBA mice and injected into random
bred albino CFLP host blastocysts (Anglia Laboratory Animals)
allowing assessment for coat colour chimaerism. No coat colour
chimaeras were obtained. Chimaerism was further assessed by
measuring the GPI-1 isozyme type of blood samples but this
indicated that the blood was also of host embryo origin in all 44
cases. Furthermore, 13 of the animals were subjected to skin grafts
from mice of the donor PGC genotype – if chimaerism was present
then these would have been recognised as ‘self’; however no grafts
survived. Finally, the potential chimaeras were test-bred and the
36 fertile animals (20 male, 16 female) produced 2695 pups, all of
which were albino. Thus, despite these exhaustive analyses no
evidence could be found that the injected PGCs contributed to the
somatic tissues or colonise the germline of the adult mice (Fig. 1B).
A subsequent attempt to introduce PGCs to early embryos used
a different method, aggregation with 8-cell embryos (Nagy et al.,
1990; Stewart, 1980). These experiments were reported in the
doctoral thesis of C.L.S (referenced in Stewart et al., 1994),
although the experimental details were not formally published.
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Fig. 1. Blastocyst injection of PGCs across the decades. (A) Schematic representation of the experimental design for the original PGC blastocyst injection experiments by
Papaioannou and Gardner. AP¼alkaline phosphatase. (B) Comparison of PGC injection experiments. No evidence of chimaerism was detected at any stage.
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PGCs were isolated from E11.5 gonads by the pricking method (de
Felici and McLaren, 1982) prior to aggregation with early 8-cell
stage embryos. After overnight culture embryos were ﬁxed and
sectioned. In 11 out of 57 cases, cells with the morphological
characteristics of PGCs were observed in the late morula/early
blastocyst. The observed cells had not divided. No embryos were
transferred to uteri to assess for chimaerism and further experi-
ments were not undertaken due to the poor adherence of PGCs to
early blastomeres. Very similar experiments were performed by G.
D. in the laboratory of Anne McLaren. Developments in transgenic
technologies allowed PGCs, and their progeny, to be tracked by
using donor mice with a β-geo transgene integrated into the
constitutively active ROSA26 locus (Friedrich and Soriano, 1991).
However, using the same experimental protocol as C.L.S, no PGCs
could be detected in the developed blastocysts by whole-mount
X-gal staining after overnight culture (data not shown). Blastocyst
injection experiments were also performed. Male and female PGCs
were kept separate and 10–15 male or 8–10 female PGCs were
injected into each blastocyst. After injection blastocysts were
cultured overnight and then transferred to recipient females.
Rather than waiting to term, chimaerism was assessed at E8.5 or
E9.5 using X-gal staining. Again no contribution of PGC-derived
cells was observed to either soma or germline (Fig. 1B).
More recent transgenic technologies have allowed PGCs to be
isolated at earlier stages in their development. Using a mil-1-GFP
transgenic line (Tanaka et al., 2004) D.O. and Y.M. were able to
isolate newly speciﬁed PGCs at E7.5 (Fig. 2A). They injected 5–10
PGCs into blastocysts, but, after 2 h of culture these PGCs were
excluded from the embryos and showed no sign of incorporation
(Fig. 2B). They then injected PGCs into 8-cell embryos
(Poueymirou et al., 2006) which were cultured for 24 h to form
blastocysts. In contrast to the results obtained in the McLaren
laboratory using E11.5 PGCs, the presence of PGCs, or PGC-derived
cells, could be observed in the cultured embryos by the continued
expression of a constitutive DsRed transgene (Fig. 2C). Further-
more, the expression of mil-1 (also known as Iﬁtm and fragilis) was
apparently downregulated in the surviving cells (Fig. 2B). Those
embryos which had apparently incorporated PGCs were trans-
ferred to pseudopregnant hosts. However, when embryos were
assessed at E6.25 no DsRed expressing cells remained, indicating a
lack of chimaerism (Fig. 1B). Notably, in these experiments injec-
tion of PGCs appeared to have a negative impact on embryogenesis
with only 18% of transferred blastocysts developing to E6.25
(Fig. 1B), compared to 58% of control embryos injected with
somatic cells (which also showed no chimaeric contribution).
Discussion
Here, for the ﬁrst time, are detailed the experimental ﬁndings
which lie behind the assertion that PGCs do not contribute to
chimaeras when introduced to the pre-implantation mouse
embryo. The studies encompass work from four independent
laboratories. The observations continue to inform current models
of the germline cycle. They have lent support to the view that PGCs
have a restricted developmental potency and cannot directly
differentiate to non-germline lineages. Thus, PGCs have been
considered unipotent and their transition to pluripotency as a
reprogramming phenomenon (Durcova-Hills et al., 2008; Kimura
and Nakano, 2011). In keeping with this there are differences in
gene expression between PGCs and pluripotent stem cells (Leitch
et al., 2013a, 2013b; Sabour et al., 2010), and epigenetic changes
which are unique to the germline (Hajkova, 2011; Ng et al., 2013)
highlighting that PGCs are a distinct cell type. However, PGCs
express pluripotency factors and can be converted into pluripotent
stem cells in vitro with remarkably high efﬁciency (Leitch et al.,
2013b). Therefore, PGCs may rather be considered to harbour a
latent or dormant form of pluripotency which is revealed during
EG cell derivation or teratocarcinogenesis (Leitch and Smith, 2013).
In either model, the distinction between the potency attributed to
PGCs, and the naïve pluripotency present in the cells of the pre-
implantation epiblast (as well as in ES and EG cells), has its
experimental underpinnings in the ﬁndings presented here.
That these results have remained unpublished reﬂects the
negative ﬁndings. It may be objected that none represents a
deﬁnitive dataset, accompanied by all the experimental controls.
However, it has to be noted that each of the laboratories involved
have extensive experience and success in generating mouse
chimaeras. For example, a contemporaneous study in the Gardner
laboratory reported that 28% of embryos injected with single ICM
cells produced live-born chimaeras (Gardner and Lyon, 1971).
Therefore, the negative results are highly unlikely to reﬂect trivial
technical failures.
So what conclusions can we draw from the data? A consistent
ﬁnding is that genital ridge stage PGCs do not contribute to
chimaeric animals. Indeed, the more recent data from G.D.
indicates that even prior to midgestation no contribution to
embryonic development is evident. Furthermore, the same
authors found no PGC derivatives in blastocyst outgrowths
initiated from embryos which had been aggregated with PGCs at
the 8-cell stage (Durcova-Hills et al., 2006). However, these
investigators did not attempt blastocyst injection with early stage
PGCs. This is an important consideration, because the properties of
PGCs are known to change dramatically as development pro-
gresses (Matsui, 1998). Furthermore, PGCs isolated at E7.5 or
E8.5 can give rise to pluripotent EG cells with very high efﬁciency,
but this capacity diminishes greatly by E11.5 (Labosky et al., 1994;
Leitch et al., 2013b). Thus, newly speciﬁed, pre-migratory PGCs
might be considered the most likely stage to demonstrate plur-
ipotency following introduction to the pre-implantation embryo.
Therefore the experiments completed in the Matsui laboratory are
particularly noteworthy.
The use of dual ﬂuorescent reporter mice allowed not only the
earliest speciﬁed PGCs to be isolated but also their in vivo
behaviour to be tracked. It is surprising that E7.5 PGCs were
excluded from the embryo following injection into the blastocoel
cavity. This was not reported for genital ridge stage PGCs. This may
be due to differential adhesive properties, which are known to
change during PGC development (de Felici and Dolci, 1989; García-
Castro et al., 1997), or to loss of cell adhesion molecules during
isolation. Further studies will be required to see if this expulsion
can be prevented, perhaps by adjusting the number of injected
cells. In contrast, the 8-cell injection experiments provide the ﬁrst
indication that PGCs, or PGC-derived cells, can continue to inter-
mingle with cells of the embryo after 24 h of culture. This
contrasts somewhat with the ﬁndings of the McLaren laboratory
published here and previously (Durcova-Hills et al., 2006). This
may be due to the injection of E7.5 PGCs, as opposed to aggrega-
tion with later genital ridge stages, or it is possible that PGCs were
lost during the subsequent blastocyst outgrowths performed in
the published study (Durcova-Hills et al., 2006). The degree to
which the PGCs are actually integrated into the host ICM remains
to be determined. Future studies should attempt to assess this in
greater detail, for instance by examining whether the cellular
properties of the injected PGCs have changed (beyond the appar-
ent downregulation of mil-1) or indeed whether apoptosis path-
ways might have been activated. Why most of the PGC-injected
embryos are subsequently lost also merits further investigation.
It is also possible that injection of fewer PGCs may allow better
survival – whether this would result in chimaeric contribution still
remains an open question. However, the preliminary data pre-
sented here suggests that like later stage PGCs, newly speciﬁed
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PGCs cannot take part in embryogenesis. It would be valuable to
conﬁrm this ﬁnding in a larger cohort of embryos, and also for
PGCs isolated at E8.0–E9.5. Given the potent effect of the cytokine
leukaemia inhibitory factor (LIF) on acquisition of pluripotency
by PGCs in culture (Leitch et al., 2013b) and in the early embryo
(Do et al., 2013) it would be interesting to test whether exposure
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Fig. 2. A modern approach to assessing the pluripotency of PGCs. (A) Phase contrast and ﬂuorescence images showing the isolation of PGCs and somatic cells from E7.5
embryos expressing bothmil1-GFP, expressed in PGCs, and a constitutively active CAG-DsRed transgene, expressed in all cells. Scale bar, 100 mm (top row) and 50 mm (bottom
two rows). (B) Phase contrast and ﬂuorescence images of blastocysts 2 h after injection with mil1-GFP positive PGCs. Scale bar, 50 mm. (C) Phase contrast and ﬂuorescence
images of embryos 24 h after injection of either PGCs or control somatic cells.Mil1-GFP-positive PGCs or GFP-negative somatic cells were injected under the zona pellucida of
8-cell stage embryos. Injected cells can still be visualised by DsRed ﬂuorescence 24 h later. Notably mil1-GFP expression was lost in the injected PGCs. Some ﬂuorescent foci
with the appearance of apoptotic fragments are also present. Scale bar, 50 mm.
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of injected 8-cell embryos to LIF might facilitate integration.
An alternative approach that may be worth considering is hetero-
topic grafting into post-implantation egg cylinder embryos, a
developmental stage closer to PGCs. This technique was recently
used to explore the in vivo developmental potential of post-
implantation epiblast stem cells (EpiSCs) (Huang et al., 2012).
The experiments presented here provide a historical account of
work that although never before published has undoubtedly
shaped our thinking about germ cell biology and pluripotency.
The advent of transgenic technologies has now improved our
ability to isolate cell populations and to track their fate after
transplantation. This highlights the opportunity for further experi-
ments to determine conclusively the developmental potency
of PGCs
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